Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium plus Metoral for prophylaxis of atrial fibrillation after coronary artery bypass grafting
IRCT20240527061915N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of magnesium and metformin in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Incidence of postoperative atrial fibrillation. Started Jun 2024; status: completed.
02
Drugs
magnesiummetformin
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20240527061915N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240527061915N1.